Propane, 1,2-epoxy-
RTECS #
TZ2975000
CAS #
Updated
December 2018
Molecular Weight
58.09
Molecular Formula
C3H6O
Synonyms
1,2-Epoxypropane
1,2-Epoxypropane (ACGIH:OSHA)
1,2-Propylene oxide
2,3-Epoxypropane
AD 6 (suspending agent)
Epoxypropane
Ethylene oxide, methyl-
Methyl ethylene oxide
Methyl oxirane
Methyloxacyclopropane
NCI-C50099
Oxirane, methyl-
Oxyde de propylene (French)
Propane, epoxy-
Propene oxide
Propylene epoxide
Propylene oxide
Propylene oxide (DOT:OSHA)
1,2-Epoxypropane (ACGIH:OSHA)
1,2-Propylene oxide
2,3-Epoxypropane
AD 6 (suspending agent)
Epoxypropane
Ethylene oxide, methyl-
Methyl ethylene oxide
Methyl oxirane
Methyloxacyclopropane
NCI-C50099
Oxirane, methyl-
Oxyde de propylene (French)
Propane, epoxy-
Propene oxide
Propylene epoxide
Propylene oxide
Propylene oxide (DOT:OSHA)
Skin and Eye Irritation and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| eye /rabbit | 20 mg | severe | AJOPAA 29,1363,1946 |
| eye /rabbit | 20 mg/24H | moderate | 85JCAE -,768,1986 |
| skin /rabbit | 415 mg open irritation test | moderate | UCDS** 12/13/1963 |
| skin /rabbit | 50 mg/6M | severe | AMIHAB 13,228,1956 |
Mutation Data and Reference
| System Test | Route/Organism/Tissue | Dose | Reference |
|---|---|---|---|
| Cytogenetic Analysis | lymphocyte/human | 1850 µg/L | MUREAV 67,101,1979 |
| Cytogenetic Analysis | liver/rat | 25 µg/L | MUREAV 153,57,1985 |
| Cytogenetic Analysis | intraperitoneal/mouse | 349 mg/kg | MUREAV 288,223,1993 |
| Cytogenetic Analysis | ovary/hamster | 160 mg/L | SCIEAS 236,933,1987 |
| DNA adduct | lymphocyte/mammal (species unspecified) | 100 mmol/tube | CBINA8 67,275,1988 |
| DNA adduct | inhalation/rat | 600 mg/kg/4W- intermittent | CRNGDP 21,2011,2000 |
| DNA adduct | inhalation/Drosophila melanogaster | 2 ppm/24H | MUREAV 529,95,2003 |
| DNA adduct | inhalation/rat | 5 ppm/3D- intermittent | CRNGDP 24,1233,2003 |
| DNA Damage | other cell types/mouse | 1.25 mmol/L | MUREAV 715,25,2011 |
| DNA Damage | leukocyte/human | 80 µmol/L/2H | MUREAV 747,1,2012 |
| DNA Damage | leukocyte/human | 100 µmol/L/24H | MUREAV 747,1,2012 |
| DNA Damage | other cell types/human | 1000 µmol/L/2H | MUREAV 747,1,2012 |
| DNA Damage | other cell types/human | 800 µmol/L/24H | MUREAV 747,1,2012 |
| DNA Damage | inhalation/rat | 25 ppm/3D- intermittent | TXAPA9 191,245,2003 |
| DNA Damage | lymphocyte/mammal (species unspecified) | 75 mmol/L | CBINA8 9,97,1974 |
| DNA Damage | liver/rat | 30 µmol/L | SinJF# 26OCT1982 |
| DNA Damage | intraperitoneal/mouse | 200 mg/kg | MUREAV 467,83,2000 |
| DNA Damage | sperm/salmon | 5 mL | ABBIA4 97,80,1962 |
| DNA Damage | testis/other fish | 5 gm | ABBIA4 97,80,1962 |
| DNA Damage | /Escherichia coli | 1 µmol/L | ARTODN 46,277,1980 |
| DNA Damage | /Other microorganisms | 1 mmol/L | MUREAV 368,235,1996 |
| Dominant Lethal Test | inhalation/rat | 300 ppm/5D- intermittent | MUREAV 117,337,1983 |
| gene conversion and mitotic recombination | /Saccharomyes cerevisiae | 25 mmol/L | MUREAV 250,229,1991 |
| heritable translocation test | parenteral/Drosophila melanogaster | 10 ppb | EMMUEG 23,208,1994 |
| micronucleus test | intraperitoneal/mouse | 600 mg/kg/24H | MUREAV 67,101,1979 |
| mutation in mammalian somatic cells | lymphocyte/mouse | 400 µg/L | SCIEAS 236,933,1987 |
| mutation in microorganisms | /Neurospora crassa | 500 mmol/L (-enzymatic activation step) | GENTAE 40,890,1955 |
| mutation in microorganisms | /Saccharomyes cerevisiae | 50 mmol/L (-enzymatic activation step) | MUREAV 250,229,1991 |
| mutation in microorganisms | /Escherichia coli | 700 µg/plate (+/-enzymatic activation step) | MUREAV 67,101,1979 |
| mutation in microorganisms | /Schizosaccharomyces pombe | 183 mmol/L (-enzymatic activation step) | ADWMAX -,193,1962 |
| mutation in microorganisms | /Salmonella typhimurium | 350 µg/plate (+enzymatic activation step) | ABCHA6 47,2461,1983 |
| mutation in microorganisms | /Salmonella typhimurium | 700 µg/plate (-enzymatic activation step) | MUREAV 67,101,1979 |
| mutation in microorganisms | /Klebsiella pneumoniae | 500 µmol/L (-enzymatic activation step) | MUREAV 89,269,1981 |
| mutation in microorganisms | /Other microorganisms | 25 mmol/L (-enzymatic activation step) | MUREAV 73,1,1980 |
| mutation in microorganisms | /Other microorganisms | 5 mmol/plate (-enzymatic activation step) | EMMUEG 23,274,1994 |
| mutation in microorganisms | /Salmonella typhimurium | 100 mg/L/2H (-enzymatic activation step) | EMMUEG 44,329,2004 |
| mutation in microorganisms | /Salmonella typhimurium | 1000 mg/L/2H (+enzymatic activation step) | EMMUEG 44,329,2004 |
| mutation in microorganisms | /Salmonella typhimurium | 50 µg/plate/72H (-enzymatic activation step) | TOXID9 228,66,2006 |
| other mutation test systems | /Salmonella typhimurium | 1 pph | ENMUDM 9,171,1987 |
| sex chromosome loss and nondisjunction | inhalation/Drosophila melanogaster | 645 ppm/24H-continuous | MUREAV 117,337,1983 |
| sex chromosome loss and nondisjunction | oral/Drosophila melanogaster | 1 ppb | EMMUEG 23,208,1994 |
| sex chromosome loss and nondisjunction | parenteral/Drosophila melanogaster | 10 ppb | EMMUEG 23,208,1994 |
| sister chromatid exchange | /Saccharomyes cerevisiae | 100 mmol/L | MUREAV 250,229,1991 |
| sister chromatid exchange | ovary/hamster | 5 mg/L | SCIEAS 236,933,1987 |
| sister chromatid exchange | lung/hamster | 2500 µmol/L | MUREAV 249,55,1991 |
| sister chromatid exchange | intraperitoneal/mouse | 232 mg/kg | MUREAV 288,223,1993 |
| sister chromatid exchange | lymphocyte/human | 25000 ppm | ENMUDM 7(Suppl 3),48,1985 |
| specific locus test | lymphocyte/mouse | 160 ppm/48H-continuous | EMMUEG 17,122,1991 |
| specific locus test | inhalation/Drosophila melanogaster | 1500 ppm | MUREAV 405,259,1998 |
| specific locus test | inhalation/Drosophila melanogaster | 3.9 ppm/24H | MUREAV 529,95,2003 |
Reproductive Effects Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/rat | 500 ppm/7H (7-16D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | NTIS** PB83-258038 |
| inhalation/rat | 500 ppm/7H (1-16D pregnant) | Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | NTIS** PB83-258038 |
| inhalation/rat | 500 ppm/7H (15D prior to copulation/1-16D pregnant) | Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) Reproductive: Effects on fertility: Litter size (e.g., # fetuses per litter; measured before birth) Reproductive: Effects on fertility: Other measures of fertility | SWEHDO 9,94,1983 |
| inhalation/monkey | 100 ppm/7H (2Y male) | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) | TOXID9 3,60,1983 |
| intraperitoneal/rat | 47 mg/kg (1D male) | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) | NEZAAQ 49,168,1994 |
| intraperitoneal/rat | 1860 mg/kg (6W male) | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Reproductive: Paternal effects: Testes, epididymis, sperm duct | NEZAAQ 49,168,1994 |
Tumorigenic Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/mouse | lowest published toxic concentration: 400 ppm/6H/2Y- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Olfaction: Tumors | JJIND8 77,573,1986 |
| inhalation/mouse | lowest published toxic concentration: 400 ppm/6H/2Y- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Olfaction: Tumors | NTPTR* NTP-TR-267,1985 |
| inhalation/mouse | lowest published toxic concentration: 24720 mg/kg/103W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Olfaction: Tumors | NTIS** PB85-179653/AS |
| inhalation/mouse | lowest published toxic concentration: 24720 mg/kg/103W- intermittent | Tumorigenic: Neoplastic by RTECS criteria Olfaction: Tumors | NTIS** PB85-179653/AS |
| inhalation/rat | toxic concentration: 400 ppm/6H/2Y- intermittent | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Olfaction: Tumors | JJIND8 77,573,1986 |
| inhalation/rat | toxic concentration: 300 ppm/6H/2.3Y- intermittent | Tumorigenic: Neoplastic by RTECS criteria Skin and Appendages: Tumors | FCTOD7 26,159,1988 |
| inhalation/rat | lowest published toxic concentration: 12360 mg/kg/103W- intermittent | Tumorigenic: Neoplastic by RTECS criteria Olfaction: Tumors | NTIS** PB85-179653/AS |
| inhalation/rat | lowest published toxic concentration: 10300 mg/kg/103W- intermittent | Tumorigenic: Neoplastic by RTECS criteria Olfaction: Tumors Endocrine: Thyroid tumors | NTIS** PB85-179653/AS |
| inhalation/rat | lowest published toxic concentration: 100 ppm/7H/2Y- intermittent | Tumorigenic: Neoplastic by RTECS criteria Endocrine: Tumors | TXAPA9 76,69,1984 |
| oral/rat | lowest published toxic dose: 10798 mg/kg/2Y- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Gastrointestinal: Tumors | BJCAAI 46,924,1982 |
| oral/rat | toxic dose: 2714 mg/kg/2Y- intermittent | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Gastrointestinal: Tumors | BJCAAI 46,924,1982 |
| subcutaneous/mouse | lowest published toxic dose: 272 mg/kg/95W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Blood: Lymphoma including Hodgkin's disease Tumorigenic: Tumors at site of application | ZHPMAT 174,383,1981 |
| subcutaneous/mouse | toxic dose: 3640 mg/kg/91W- intermittent | Tumorigenic: Neoplastic by RTECS criteria Blood: Lymphoma including Hodgkin's disease Tumorigenic: Tumors at site of application | BJCAAI 39,588,1979 |
| subcutaneous/mouse | toxic dose: 868 mg/kg/95W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Blood: Lymphoma including Hodgkin's disease Tumorigenic: Tumors at site of application | ZHPMAT 174,383,1981 |
| subcutaneous/mouse | toxic dose: 2912 mg/kg/95W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Blood: Lymphoma including Hodgkin's disease Tumorigenic: Tumors at site of application | ZHPMAT 174,383,1981 |
| subcutaneous/mouse | toxic dose: 6616 mg/kg/95W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Blood: Lymphoma including Hodgkin's disease Tumorigenic: Tumors at site of application | ZHPMAT 174,383,1981 |
| subcutaneous/rat | lowest published toxic dose: 1500 mg/kg/46W- intermittent | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Tumorigenic: Facilitates action of known carcinogens | ANYAA9 68,750,1958 |
Acute Toxicity Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/Dog | Lowest published lethal concentration: 2005 ppm/4H | Olfaction: Other olfaction effects Eye: Lacrimation Gastrointestinal: Nausea or vomiting | AMIHAB 13,237,1956 |
| inhalation/guinea pig | Lowest published lethal concentration: 4000 ppm/4H | Eye: Iritis Behavioral: Muscle weakness Lung, Thorax, or Respiration: Dyspnea | AMIHAB 13,228,1956 |
| inhalation/man | lowest published toxic concentration: 1400 gm/m3/10M | Behavioral: Somnolence (general depressed activity) Behavioral: Headache Gastrointestinal: Nausea or vomiting | GTPZAB 15(2),48,1971 |
| inhalation/mouse | lethal concentration (50 percent kill): 1740 ppm/4H | Olfaction: Other olfaction effects Lung, Thorax, or Respiration: Dyspnea Gastrointestinal: Changes in structure or function of salivary glands | AMIHAB 13,237,1956 |
| inhalation/rat | lethal concentration (50 percent kill): 4000 ppm/4H | Olfaction: Other olfaction effects Eye: Lacrimation Lung, Thorax, or Respiration: Dyspnea | AMIHAB 13,237,1956 |
| intraperitoneal/mouse | lethal dose (50 percent kill): 175 mg/kg | 85GMAT -,103,1982 | |
| intraperitoneal/rat | lethal dose (50 percent kill): 150 mg/kg | 85GMAT -,103,1982 | |
| oral/guinea pig | lethal dose (50 percent kill): 660 mg/kg | Behavioral: Somnolence (general depressed activity) Liver: Other changes Kidney, Ureter, and Bladder: Other changes | GISAAA 46(7),76,1981 |
| oral/mammal (species unspecified) | lethal dose (50 percent kill): 440 mg/kg | GISAAA 39(4),86,1974 | |
| oral/mouse | lethal dose (50 percent kill): 440 mg/kg | Behavioral: Excitement Behavioral: Ataxia Lung, Thorax, or Respiration: Respiratory stimulation | GTPZAB 14(11),55,1970 |
| oral/rat | lethal dose (50 percent kill): 380 mg/kg | Behavioral: Excitement Behavioral: Ataxia Lung, Thorax, or Respiration: Respiratory stimulation | GTPZAB 14(11),55,1970 |
| skin/rabbit | lethal dose (50 percent kill): 1500 µL/kg | AIHAAP 30,470,1969 |
Other Multiple Dose Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/guinea pig | lowest published toxic concentration: 457 ppm/7H/22W- intermittent | Eye: Other eye effects Lung, Thorax, or Respiration: Changes in lung weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain | AMIHAB 13,228,1956 |
| inhalation/mouse | lowest published toxic concentration: 487 ppm/6H/2W- intermittent | Behavioral: Somnolence (general depressed activity) Lung, Thorax, or Respiration: Dyspnea | NTPTR* NTP-TR-267,1985 |
| inhalation/mouse | lowest published toxic concentration: 125 ppm/6H/13W- intermittent | Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTPTR* NTP-TR-267,1985 |
| inhalation/mouse | lowest published toxic dose: 200 ppm/6H/4W- intermittent | Olfaction: Other olfaction effects Lung, Thorax, or Respiration: Other changes | TOXID9 -,109,2008 |
| inhalation/rat | lowest published toxic concentration: 51.6 ppm/3D- intermittent | Olfaction: Other olfaction effects | TOLED5 185,203,2009 |
| inhalation/rat | lowest published toxic concentration: 50 ppm/6H/3D- intermittent | Biochemical: Metabolism (intermediary): Other | NSAPCC 375(Suppl 1),88,2007 |
| inhalation/rat | lowest published toxic concentration: 100 ppm/6H/3D- intermittent | Olfaction: Other olfaction effects Biochemical: Metabolism (intermediary): Other | NSAPCC 375(Suppl 1),88,2007 |
| inhalation/rat | lowest published toxic dose: 400 ppm/6H/4W- intermittent | Olfaction: Other olfaction effects Lung, Thorax, or Respiration: Other changes | TOXID9 -,109,2008 |
| inhalation/rat | lowest published toxic concentration: 457 ppm/7H/28W- intermittent | Eye: Other eye effects Lung, Thorax, or Respiration: Fibrosis, focal (pneumoconiosis) Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | AMIHAB 13,228,1956 |
| inhalation/rat | lowest published toxic concentration: 1433 ppm/6H/12D- intermittent | Lung, Thorax, or Respiration: Dyspnea Gastrointestinal: Hypermotility, diarrhea Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTPTR* NTP-TR-267,1985 |
| inhalation/rat | lowest published toxic concentration: 25 mg/m3/4H/26W- intermittent | Brain and Coverings: Changes in surface EEG Brain and Coverings: Other degenerative changes Vascular: BP lowering not characterized in autonomic section | GTPZAB 14(11),55,1970 |
| inhalation/rat | lowest published toxic concentration: 529 ppm/6H/4W- intermittent | Olfaction: Other olfaction effects | FAATDF 27,25,1995 |
| inhalation/rat | lowest published toxic concentration: 997 ppm/6H/2W- intermittent | Cardiac: Changes in heart weight Lung, Thorax, or Respiration: Structural or functional change in trachea or bronchi Nutritional and Gross Metabolic: Weight loss or decreased weight gain | NTPTR* OTS0535203 |
| oral/rat | lowest published toxic dose: 1170 mg/kg/45D- intermittent | Brain and Coverings: Other degenerative changes Liver: Other changes Blood: Other changes | GISAAA 46(7),76,1981 |
Reviews
| Organization | Standard | Reference |
|---|---|---|
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 2 ppm (sen) | DTLVS* TLV/BEI,2013 |
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-Confirmed animal carcinogen | DTLVS* TLV/BEI,2013 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Animal Sufficient Evidence | IMEMDT 36,227,1985 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Animal Sufficient Evidence | IMEMDT 60,181,1994 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMEMDT 36,227,1985 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMEMDT 60,181,1994 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Group 2B | IMEMDT 60,181,1994 |
| TOXICOLOGY REVIEW | MUREAV 543,201,2003 | |
| TOXICOLOGY REVIEW | TOLED5 140-141,53,2003 | |
| TOXICOLOGY REVIEW | MUREAV 567,227,2004 | |
| TOXICOLOGY REVIEW | MUREAV 567,151,2004 | |
| TOXICOLOGY REVIEW | MUREAV 580,91,2005 | |
| TOXICOLOGY REVIEW | EMMUEG 39,69,2002 | |
| TOXICOLOGY REVIEW | MUTAEX 15,431,2000 | |
| TOXICOLOGY REVIEW | MUREAV 627,10,2007 | |
| TOXICOLOGY REVIEW | BCLPT* 96,131,2005 | |
| TOXICOLOGY REVIEW | MUREAV 584,1,2005 | |
| TOXICOLOGY REVIEW | HETOEA 25,413,2006 | |
| TOXICOLOGY REVIEW | FEREAC 73,31788,2008 | |
| TOXICOLOGY REVIEW | FEREAC 72,49646,2007 | |
| TOXICOLOGY REVIEW | FEREAC 73,54954,2008 | |
| TOXICOLOGY REVIEW | TXAPA9 243,180,2010 | |
| TOXICOLOGY REVIEW | MUREAV 705,107,2010 | |
| TOXICOLOGY REVIEW | MUREAV 678,76,2009 | |
| TOXICOLOGY REVIEW | MUREAV 752,99,2013 | |
| TOXICOLOGY REVIEW | FCTOD7 55,596,2013 | |
| TOXICOLOGY REVIEW | MUREAV 769,34,2014 | |
| TOXICOLOGY REVIEW | MUREAV 802,1,2016 | |
| TOXICOLOGY REVIEW | MUREAV 770,170,2016 | |
| TOXICOLOGY REVIEW | RTOPDW 54,247,2009 | |
| TOXICOLOGY REVIEW | RTOPDW 55,43,2009 |
Standards and Regulations
| Organization | Standard | Reference |
|---|---|---|
| Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION | FEREAC 54,7740,1989 | |
| Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1998 STATUS OF PESTICIDES | Supported | RBREV* -,204,1998 |
| Mine Safety and Health Administration (MSHA) STANDARD-air | time-weighted average 100 ppm (240 mg/m3) | DTLVS* 3,219,1971 |
| Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
| Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
| Occupational Exposure Limit-AUSTRALIA | time-weighted average 20 ppm (48 mg/m3), Carcinogen, JUL2008 | |
| Occupational Exposure Limit-AUSTRIA | TRK-TMW 2.5 ppm (6 mg/m3);KZW 10 ppm (24 mg/m3), skin, 2007 | |
| Occupational Exposure Limit-BELGIUM | time-weighted average 2 ppm (5 mg/m3), Carcinogen, MAR2002 | |
| Occupational Exposure Limit-DENMARK | time-weighted average 5 ppm (12 mg/m3), skin, carc, MAY2011 | |
| Occupational Exposure Limit-FINLAND | time-weighted average 1 ppm (2.4 mg/m3), skin, NOV2011 | |
| Occupational Exposure Limit-FRANCE | VME 20 ppm (50 mg/m3), C2 Carcinogen, FEB2006 | |
| Occupational Exposure Limit-HUNGARY | ceiling concentration 5 mg/m3, Skin, Carcinogen, SEP2000 | |
| Occupational Exposure Limit-ICELAND | time-weighted average 5 ppm (12 mg/m3), carc, skin, NOV2011 | |
| Occupational Exposure Limit-JAPAN | 2B carc, MAY2012 | |
| Occupational Exposure Limit-KOREA | time-weighted average 20 ppm (50 mg/m3), 2006 | |
| Occupational Exposure Limit-MEXICO | time-weighted average 20 ppm (50 mg/m3), 2004 | |
| Occupational Exposure Limit-NEW ZEALAND | time-weighted average 5 ppm (12 mg/m3), JAN2002 | |
| Occupational Exposure Limit-PERU | time-weighted average 2 ppm (5 mg/m3), JUL2005 | |
| Occupational Exposure Limit-RUSSIA | short term exposure limit 1 mg/m3, Skin, JUN2003 | |
| Occupational Exposure Limit-SWEDEN | time-weighted average 2 ppm (5 mg/m3);short term exposure limit 10 ppm (25 mg/m3), Carcinogen, JUN2005 | |
| Occupational Exposure Limit-SWITZERLAND | MAK-week 2.5 ppm (6 mg/m3), carc 2, skin, JAN2011 | |
| Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 6 mg/m3, 2003 | |
| Occupational Exposure Limit-THE PHILIPPINES | time-weighted average 100 ppm (240 mg/m3), JAN1993 | |
| Occupational Exposure Limit-TURKEY | time-weighted average 100 ppm (240 mg/m3), JAN1993 | |
| Occupational Exposure Limit-UNITED KINGDOM | time-weighted average 5 ppm (12 mg/m3), OCT2007 | |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) | 8H time-weighted average 100 ppm (240 mg/m3) | CFRGBR 29,1926.55,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) | 8H time-weighted average 100 ppm (240 mg/m3) | CFRGBR 41,50-204.50,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) | 8H time-weighted average 100 ppm (240 mg/m3) | CFRGBR 29,1910.1000,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) | 8H time-weighted average 100 ppm (240 mg/m3) | CFRGBR 29,1915.1000,1993 |
NIOSH Documentation and Surveillance
| Organization | Standard | Reference |
|---|---|---|
| National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO PROPYLENE OXIDE-air | Carcinogen lowest feasible concentrtion | NIOSH* DHHS #92-100,1992 |
| National Occupational Exposure Survey 1983 | Hazard Code 63550; Number of Industries 57; Total Number of Facilities 5786; Number of Occupations 67; Total Number of Employees Exposed 421140; Total Number of Female Employees Exposed 317309 | |
| National Occupational Hazard Survey 1974 | Hazard Code 63550; Number of Industries 78; Total Number of Facilities 9032; Number of Occupations 60; Total Number of Employees Exposed 75135 |
Status in Federal Agencies
| Organization | Reference |
|---|---|
| EPA GENETOX PROGRAM 1988, Negative: Rodent dominant lethal | |
| EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat; Cell transform.-SA7/SHE | |
| EPA GENETOX PROGRAM 1988, Positive: CHO gene mutation | |
| EPA GENETOX PROGRAM 1988, Positive: N crassa-reversion; D melanogaster Sex-linked lethal | |
| EPA GENETOX PROGRAM 1988, Positive: S pombe-reversion | |
| EPA TSCA 8(a) PRELIMINARY ASSESSMENT INFORMATION, FINAL RULE | FEREAC 47,26992,82 |
| EPA TSCA Section 8(b) CHEMICAL INVENTORY | |
| EPA TSCA Section 8(d) unpublished health/safety studies | |
| EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001 | |
| NCI Carcinogenesis Studies (inhal);clear evidence:mouse | |
| NCI Carcinogenesis Studies (inhal);equivocal evidence:rat | |
| NIOSH Analytical Method, 1994: Propylene oxide, 1612 | |
| NIOSH CURRENT INTELLIGENCE BULLETIN 51, JULY 1989 | |
| NTP 14th Report on Carcinogens,2016:Reasonably anticipated to be human carcinogen | |
| NTP Carcinogenesis Studies (inhalation);some evidence:rat NTPTR* NTP-TR-267,1985 | |
| On EPA IRIS database | |
| OSHA ANALYTICAL METHOD #88 |
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health